Cancer Research Prevention Award Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, L.
Right arrow Articles by Morgan, J. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, L.
Right arrow Articles by Morgan, J. I.
[Cancer Research 63, 2733-2736, June 1, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Mouse Embryos Cloned from Brain Tumors1

Leyi Li, Michele C. Connelly, Cynthia Wetmore2, Tom Curran and James I. Morgan3

Department of Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
Cancer cells escape from growth control by accumulating genetic and epigenetic alterations. In rare instances, epigenetic changes alone are oncogenic. Furthermore, agents that modify DNA methylation or chromatin structure can restore a normal phenotype to cells harboring oncogenic mutations. However, it is unclear to what extent epigenetic reprogramming can reverse oncogenesis. Using somatic nuclear transfer, we show that medulloblastomas arising in Ptc1+/- mice can direct preimplantation development. Additionally, blastocysts derived from medulloblastoma nuclei form postimplantation embryos with typical cell layers. Thus, tumor cells can be epigenetically reprogrammed into normal cell types. This approach could lead to a general strategy for assessing genetic and epigenetic contributions to tumorigenesis.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
Cancers arise through the accumulation of genetic mutations (1) and epigenetic modifications (2 , 3) . Although many proto-oncogenes and tumor suppressor genes are widely expressed, the mutation of these genes is associated with cancer of specific organs or cell types (4 , 5) . This suggests that, to some extent, malignant growth depends on epigenetic factors that are governed by the cellular context in which a tumor arises. Teratocarcinomas can arise through purely epigenetic changes and represent an extreme case in which the transformed phenotype can be abrogated under appropriate conditions (6, 7, 8) . Indeed, in early chimera studies, it was demonstrated that teratocarcinoma cells are able to contribute to the germ line, ultimately giving rise to adult mice (6) . In a frog renal carcinoma model, the transfer of nuclei from tumor cells into oocytes was reported to reverse oncogenesis and to direct development to the tadpole stage (9) . Although this was suggested to occur through epigenetic reprogramming, subsequently it was found that the transforming gene, which was encoded by a Herpesvirus episome (10) , was lost during the nuclear transfer procedure (11) . Here, we investigate the possibility of whether a tumor cell nucleus, in which transformation is caused by somatic mutation, can be epigenetically reprogrammed into normal tissues.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS AND DISCUSSION
 REFERENCES
 
Tumor Cell Culture.
Medulloblastomas were collected from Ptc1 heterozygous mice and minced, and dissociated cells were cultured on poly-D-lysine in DMEM supplemented with 2 mM L-glutamine and 10% fetal bovine serum at 37°C in 10% CO2 in air. Subsequently, cells were passaged in the same medium after detachment with trypsin. For immunohistochemistry, cells were fixed in 4% paraformaldehyde and were processed according to standard techniques with antibodies to medium and heavy chains of neurofilament (1:200; Zymed Laboratories, San Francisco, CA), synaptophysin (1:100; Zymed Laboratories), neuron-specific enolase (1:200; DAKO Corporation, Carpinteria, CA), or GFAP4 (1:200; DAKO Corporation). Bound antibodies were detected using appropriate secondary antibodies conjugated to Texas Red-X or Oregon Green 500 (each, 1:500; Molecular Probes, Eugene, OR).

Nuclear Transfer.
Female B6D2F1 mice were superovulated, and oocytes were harvested according to standard techniques (12) . An enucleation pipette attached to a PiezoDrill (Burleigh, NY) was used to cut through the zona pellucida, and the metaphase II spindle was aspirated (removal was confirmed by Hoechst 33258 staining). Subsequent transfer of medulloblastoma nuclei and embryo culture was as described by Wakayama et al. (13) .

Genotyping.
DNA was isolated from embryos, deciduas, and surrounding uterine tissue by standard techniques. Genotyping was performed using PCR for lacZ and neo genes contained within the Ptc1 targeting vector (14) . One set of primers (5'-GCTGGGATCCGCCATTGTCAGACATG-3' and 5'-GCTGGAATTCCGCCGATACTGAC-3') amplified a 295-bp fragment of the lacZ gene whereas the other set amplified a 520-bp fragment of the neo gene. PCR for lacZ was run for 30 cycles with denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 30 s. PCR products were analyzed on a 1.0% agarose gel.


   RESULTS AND DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
REFERENCES
 
Medulloblastoma, the most common malignant pediatric brain tumor, originates from granule neuron precursors in the developing cerebellum (15) . Ptc1, a tumor suppressor gene, has been implicated in familial and sporadic medulloblastoma in humans (16) . Furthermore, ~14% of Ptc1 heterozygous mice develop medulloblastoma (14 , 17) , but the incidence increases to ~95% in the absence of p53 (18) , which suggests that additional mutations contribute to tumorigenesis. We cultured cells from tumors arising spontaneously in two female Ptc1+/- mice at 3 months (SJMM4) and 7 months (SJMM2) of age, respectively. These tumor cells were chosen for investigation, because their karyotypes were grossly normal during early passages, an important criterion for nuclear transfer. Transplantation of SJMM2 and SJMM4 directly into the flank of immunodeficient mice resulted in tumor formation; and SJMM2, at passage 10, formed colonies in soft agar. Although the levels of Ptc1 were low in the majority of cultures examined, SJMM2 expressed very high steady-state levels of protein.

Simultaneous expression of both neural and glial markers is a feature characteristic of medulloblastoma (15) . After passage three, the great majority of cultured cells coexpressed glial and neuronal markers, including GFAP, neurofilament (Fig. 1)Citation , neuron-specific enolase, and synaptophysin. Although the tumors from which the cell cultures were derived could be grown in allografts and formed colonies in agar at passage 12 and 13 (SJMM2), it is formally possible that some of the cultured cells lost their tumorigenic capacity during monolayer culture. The cells were used for nuclear transfer between passage 5 and 12 to completely exclude contamination by non-tumor-derived neuronal cells, which do not survive passage in culture, and to minimize the accumulation of mutations arising in culture. To assess the reproducibility of phenotypes, multiple batches of cells from each passage were used. Normal mouse spleen cells (from B6D2F1 mice) were used as a source of control nuclei to compare the efficiency of developmental progression after nuclear transfer.



View larger version (50K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Expression of neuronal and glial markers in cells cultured from the SJMM2 medulloblastoma. Confocal images of: A, neurofilament medium and heavy chains; B, GFAP; C, merge, neurofilament and GFAP. Similar colocalization was observed in cells from the SJMM4 medulloblastoma and with antibodies to neuron-specific enolase and synaptophysin. Scale bar, 20 µm.

 
The initial stage of preimplantation development involves nuclear remodeling and the formation of pronuclei (12) . The order and timing of cell division and differentiation during preimplantation development is geared strictly to a zygotic clock (19) . Therefore, if the transferred medulloblastoma nuclei do not cease uncontrolled cell proliferation, they would not be able to direct preimplantation development. After transfer (n = 1669), ~75% of medulloblastoma nuclei increased dramatically in size (Fig. 2, A–C)Citation and subsequently formed pronuclei with one or more pronucleolus within 24 h (Fig. 2CCitation ; Table 1Citation ). For comparison, ~84% of spleen cell-derived nuclei (n = 212) progressed to the same stage (Table 1)Citation . 72 h after activation, ~27% of the transferred oocytes had progressed to the 2-cell stage (Fig. 2DCitation ; Table 1Citation ), 10% to the 4/8-cell stage (Fig. 2, E and FCitation ; Table 1Citation ), and 10% had developed into morulae or blastocysts (Fig. 2, G and HCitation ; Table 1Citation ). No substantial differences in cloning efficiency were observed between the two tumor cell cultures (Table 1)Citation or among cells from different passage numbers. The equivalent results for spleen cell-derived nuclei were 35, 17, and 29%, respectively (Table 1)Citation . This apparent enhanced efficiency seems to be related to the increased number of cloned embryos that die soon after transfer (Table 1)Citation , possibly as a result of the more stringent methods required to remove nuclei from tumor cells. Noticeably, although medulloblastoma-derived embryos died, none exhibited uncontrolled proliferation resembling tumorigenesis.



View larger version (75K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Nuclear remodeling and preimplantation development of transplanted medulloblastoma nuclei. A, SJMM2 medulloblastoma cells in culture. B, enucleated oocytes immediately after the injection of medulloblastoma nuclei (arrowheads). C, activated oocytes with pronuclei formed from medulloblastoma nuclei; arrows, pronuclei containing prominent pronucleoli. D, 2-cell cloned embryos. E, 4-cell cloned embryos. F, 8-cell cloned embryos. G, pre- and postcompaction cloned morulae. H, cloned blastocyst. I, hatching cloned blastocyst. J, ICM explant derived from a cloned blastocyst. All of the panels are at same magnification. Scale bar, 20 µm.

 

View this table:
[in this window]
[in a new window]

  		Table 1 Development of embryos from transplanted medulloblastoma nuclei in vitro

 
Blastocysts derived from medulloblastoma were morphologically indistinguishable from those derived from spleen cell nuclei: they formed blastocyst cavities surrounded by trophoblast cells, and ICMs could be identified (Fig. 2H)Citation . Blastocyst cavities gradually accumulated fluid and expanded, and, when maintained for longer periods, blastocysts hatched from the zona pellucida (Fig. 2I)Citation . Again, there was no evidence of the uncontrolled cell growth characteristic of cultured tumor cells.

We cultivated medulloblastoma-derived blastocysts for extended periods under the same conditions that were used to propagate the parental medulloblastoma cells. After 2 days in culture, blastocysts hatched from the zona pellucida, trophoblast cells spread onto the culture dishes, and an ICM formed in the center of the expanded trophoblast regions (Fig. 2J)Citation . The ICM cells subsequently differentiated, and, in marked contrast to medulloblastoma cells, both trophoblasts and ICM cells ceased proliferation. Thus, reprogrammed medulloblastoma nuclei lost the capacity for extensive proliferation characteristic of tumor cells in vitro.

Postimplantation development occurs under conditions of even more rigid and complex control than preimplantation development (12) . To establish whether medulloblastoma-derived embryos could direct later stages of development, we transferred cloned blastocysts into pseudo-pregnant females. Recipients were sacrificed at various stages of pregnancy, and decidua were fixed and sectioned or were processed for DNA analysis. Although evidence of implantation was observed even at late stages of gestation, no viable embryos were recovered subsequent to E8.5. Even when maintained well past term, none of the recipients developed tumors (n = 29). However, we were able to identify viable embryos and embryos undergoing resorption at E7.5 and E8.5. At 7.5 days of development, the embryos appeared grossly normal, and they contained embryonic ectoderm, mesoderm, endoderm, ectoplacental cones, chorion, amnion, Reichert’s membrane, yolk sac cavity, and amniotic cavity (Fig. 3)Citation . Later embryos (8.5 days of development) showed more extensive differentiation with cephalic vesicles and neural tube.



View larger version (123K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. A day 7.5 embryo derived from a transplanted SJMM4 medulloblastoma nucleus stained with H&E. B, a higher magnification of the boxed area in A to show the three distinguishable germ layers. pla, ectoplacental cone; end, embryonic endoderm; mes, embryonic mesoderm; ect, embryonic ectoderm. Scale bar, 20 µm.

 
To confirm that the postimplantation embryos originated from transplanted medulloblastoma nuclei, we performed PCR to identify the ß-galactosidase (lacZ) and neomycin resistance (neo) genes present in the targeting vector. A 295-bp amplicon from lacZ and a 520-bp amplicon from Ptc1-neo were detected in the decidua and embryos, although surrounding uterine tissues were negative for both genes (Fig. 4)Citation .



View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. PCR confirmation of the presence of lacZ and neo genes in postimplantation embryos derived from transplanted medulloblastoma nuclei. Lane 1, positive control; Lane 6, negative control. Lanes 2 and 3 contain DNA extracted from implantations No. 1 (E8.5-day embryo derived from SJMM2) and No. 4 (E6.5-day embryo derived from SJMM4), respectively. Lanes 4 and 5 contain DNA extracted from maternal uterine tissues from recipients for implantations No. 1 and No. 4, respectively. Arrows, the positions of authentic lacZ, neo, and Ptc1 amplicons. The endogenous Ptc1 allele serves as DNA loading control.

 
These results demonstrate that epigenetic reprogramming of medulloblastoma nuclei by somatic nuclear transfer abrogates the tumorigenic phenotype: uncontrolled proliferation is suppressed and normal patterns of differentiation are restored. Although transplanted medulloblastoma nuclei are less efficient than spleen cell-derived nuclei, they, nevertheless, directed all of preimplantation development. Moreover, they gave rise to postimplantation embryos that had undergone tissue differentiation and early stages of organogenesis. Remarkably, no malignancies were observed in any of the recipient mice, and normal proliferation control was observed in cultured blastocysts. Thus, the tumorigenic mutations that underlie medulloblastoma must act within the context of the cerebellar granule cell lineage, and those changes will not necessarily support malignant cell proliferation in the context of other cell lineages. It will now be important to establish whether the medulloblastoma nuclei preferentially produce tumors in the cerebellum using chimeric mouse approaches. This analysis may also reveal whether medulloblastoma-derived nuclei harbor mutations that preclude further embryonic development or the genesis of specific tissue types. The successful reprogramming of medulloblastoma nuclei by somatic nuclear transfer encourages exploration of the utility of anticancer agents that target chromatin and DNA methylation for the treatment of this devastating pediatric cancer.


   ACKNOWLEDGMENTS
 
We thank Karen Forbes, Hiro Kimura, Jennifer Parris, and Nichola Wigle for technical expertise and Drs. Mary Dickinson, Ciaran Faherty, Brigid Hogan, Andy MacMahon, and Teruhiko Wakayama for advice and discussions.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by NIH Cancer Center Support CORE Grant CA21765, the American Lebanese Syrian Associated Charities (ALSAC), and the Pediatric Brain Tumor Foundation of the United States (to C. W.); NIH Grants CA 84139, CA 96832 and NS 36558 (to T. C.); and NIH Grants NS 40361, NS 40749, and ES 10772 (to J. I. M.). Back

2 Present address: Division of Pediatric Hematology/Oncology, Mayo Clinic and Cancer Center, Rochester, MN 55905. Back

3 To whom requests for reprints should be addressed, at Department of Developmental Neurobiology, St. Jude Children’s Research Hospital, 332 North Lauderdale, Memphis, Tennessee 38105. E-mail: jim.morgan{at}stjude.org Back

4 The abbreviations used are: GFAP, glial fibrillary acidic protein; ICM, inner cell mass. Back

Received 4/10/03. Accepted 4/16/03.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Knudson A. G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer, 1: 157-162, 2001.[Medline]
  2. Baylin S. B., Herman J. G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet., 16: 168-174, 2000.[Medline]
  3. Jones P. A., Laird P. W. Cancer epigenetics comes of age. Nature Genetics, 21: 163-167, 1999.[Medline]
  4. Knudson A. G. Hereditary predisposition to cancer. Ann. N. Y. Acad. Sci., 833: 58-67, 1997.[Medline]
  5. Fearon E. R. Human cancer syndromes: clues to the origin and nature of cancer. Science (Wash. DC), 278: 1043-1050, 1997.[Abstract/Free Full Text]
  6. Mintz B., Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. USA, 72: 3585-3589, 1975.[Abstract/Free Full Text]
  7. Papaioannou V. E., McBurney M. W., Gardner R. L., Evans M. J. Fate of teratocarcinoma cells injected into early mouse embryos. Nature (Lond.), 258: 70-73, 1975.[Medline]
  8. Illmensee K., Mintz B. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc. Natl. Acad. Sci. USA, 73: 549-553, 1976.[Abstract/Free Full Text]
  9. McKinnell R. G., Deggins B. A., Labat D. D. Transplantation of pluripotential nuclei from triploid frog tumors. Science (Wash. DC), 165: 394-396, 1969.[Abstract/Free Full Text]
  10. Naegele R. F., Granoff A., Darlington R. W. The presence of the Lucke herpesvirus genome in induced tadpole tumors and its oncogenicity: Koch-Henle postulates fulfilled. Proc. Natl. Acad. Sci. USA, 71: 830-834, 1974.[Abstract/Free Full Text]
  11. Carlson D. L., Sauerbier W., Rollins-Smith L. A., McKinnell R. G. Fate of herpesvirus DNA in embryos and tadpoles cloned from Lucke renal carcinoma nuclei. J. Comp. Pathol., 111: 197-204, 1994.[Medline]
  12. Hogan B., Beddington R., Costantini F., Lacy E. . Manipulating the Mouse Embryo, CSHL Press New York 1994.
  13. Wakayama T., Perry A. C., Zuccotti M., Johnson K. R., Yanagimachi R. Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature (Lond.), 394: 369-374, 1998.[Medline]
  14. Goodrich L. V., Milenkovic L., Higgins K. M., Scott M. P. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science (Wash. DC), 277: 1109-1113, 1997.[Abstract/Free Full Text]
  15. Russel D. S., Rubinstein L. J. . Pathology of Tumors of the Nervous System, 1: 456-479, Oxford University Press New York 1998.
  16. Weiss W. A. Genetics of brain tumors. Curr. Opin. Pediatr., 12: 543-548, 2000.[Medline]
  17. Wetmore C., Eberhart D. E., Curran T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res., 60: 2239-2246, 2000.[Abstract/Free Full Text]
  18. Wetmore C., Eberhart D. E., Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res., 61: 513-516, 2001.[Abstract/Free Full Text]
  19. Nothias J. Y., Majumder S., Kaneko K. J., DePamphilis M. L. Regulation of gene expression at the beginning of mammalian development. J. Biol. Chem., 270: 22077-22080, 1995.[Free Full Text]



This article has been cited by other articles:


Home page
 DevelopmentHome page
K. Hochedlinger and K. Plath
Epigenetic reprogramming and induced pluripotency
Development, February 15, 2009; 136(4): 509 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
J. D. Kessler, H. Hasegawa, S. N. Brun, B. A. Emmenegger, Z.-J. Yang, J. W. Dutton, F. Wang, and R. J. Wechsler-Reya
N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma
Genes & Dev., January 15, 2009; 23(2): 157 - 170.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
X. Fan and C. G. Eberhart
Medulloblastoma Stem Cells
J. Clin. Oncol., June 10, 2008; 26(17): 2821 - 2827.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Sasai, J. T. Romer, H. Kimura, D. E. Eberhart, D. S. Rice, and T. Curran
Medulloblastomas Derived from Cxcr6 Mutant Mice Respond to Treatment with a Smoothened Inhibitor
Cancer Res., April 15, 2007; 67(8): 3871 - 3877.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Sasai, J. T. Romer, Y. Lee, D. Finkelstein, C. Fuller, P. J. McKinnon, and T. Curran
Shh pathway activity is down-regulated in cultured medulloblastoma cells: implications for preclinical studies.
Cancer Res., April 15, 2006; 66(8): 4215 - 4222.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
K. Baverstock and O. V Belyakov
Classical radiation biology, the bystander effect and paradigms: a reply
Human and Experimental Toxicology, October 1, 2005; 24(10): 537 - 542.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
C. Hong, A. Maunakea, P. Jun, A. W. Bollen, J. G. Hodgson, D. D. Goldenberg, W. A. Weiss, and J. F. Costello
Shared Epigenetic Mechanisms in Human and Mouse Gliomas Inactivate Expression of the Growth Suppressor SLC5A8
Cancer Res., May 1, 2005; 65(9): 3617 - 3623.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
S. Wakayama, H. Ohta, S. Kishigami, N. Van Thuan, T. Hikichi, E. Mizutani, M. Miyake, and T. Wakayama
Establishment of Male and Female Nuclear Transfer Embryonic Stem Cell Lines from Different Mouse Strains and Tissues
Biol Reprod, April 1, 2005; 72(4): 932 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. H. Blelloch, K. Hochedlinger, Y. Yamada, C. Brennan, M. Kim, B. Mintz, L. Chin, and R. Jaenisch
Inaugural Article: Nuclear cloning of embryonal carcinoma cells
PNAS, September 28, 2004; 101(39): 13985 - 13990.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
K. Hochedlinger, R. Blelloch, C. Brennan, Y. Yamada, M. Kim, L. Chin, and R. Jaenisch
Reprogramming of a melanoma genome by nuclear transplantation
Genes & Dev., August 1, 2004; 18(15): 1875 - 1885.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
S.-C. Ng, N. Chen, W.-Y. Yip, S.-L. Liow, G.-Q. Tong, B. Martelli, L. G. Tan, and P. Martelli
The first cell cycle after transfer of somatic cell nuclei in a non-human primate
Development, May 15, 2004; 131(10): 2475 - 2484.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
R. JAENISCH, K. HOCHEDLINGER, R. BLELLOCH, Y. YAMADA, K. BALDWIN, and K. EGGAN
Nuclear Cloning, Epigenetic Reprogramming, and Cellular Differentiation
Cold Spring Harb Symp Quant Biol, January 1, 2004; 69(0): 19 - 28.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, L.
Right arrow Articles by Morgan, J. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, L.
Right arrow Articles by Morgan, J. I.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online